Approved regulatory verdict
Evidence outlook
Approved: Acetaminophen Overdose
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
How the evidence outlook works ↗
Featured trials The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Idiopathic Pulmonary Fibrosis · investigational · Featured evidence · 2 Heart Disease · not a covered market · Outside covered markets · 1 Respiratory Tract Diseases · not a covered market · Outside covered markets · 1 investigational Featured evidence · 2
Competitive landscape No competitors sharing a mechanism or indication in the current universe.
Upcoming events (12 total) Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (3) November 2026 (1) Early phase / not applicable Prodromal Schizophrenia Recruiting
Est. primary completion 2026-11-01 ·
NCT05142735 ·
CT.gov ↗ What to watch December 2026 (2) Phase 2 Triple Negative Breast Cancer, Vitamin D Deficiency, Invasive Breast Cancer Recruiting
Est. primary completion 2026-12 ·
NCT04677816 ·
CT.gov ↗ What to watch Phase 3 Psychosis Recruiting
Est. primary completion 2026-12-15 ·
NCT05796401 ·
CT.gov ↗ What to watch 2027 (6) February 2027 (1) Phase 2 Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive Active not recruiting
Est. primary completion 2027-02 ·
NCT05122559 ·
CT.gov ↗ What to watch March 2027 (1) Phase 2 Systemic Lupus Erythematosus Active not recruiting
Est. primary completion 2027-03-31 ·
NCT00775476 ·
CT.gov ↗ What to watch April 2027 (1) Phase 4 Asthma, COPD Active not recruiting
Est. primary completion 2027-04 ·
NCT06152653 ·
CT.gov ↗ What to watch June 2027 (1) Phase 2 Breast Cancer Recruiting
Est. primary completion 2027-06 ·
NCT07117630 ·
CT.gov ↗ What to watch July 2027 (2) Early phase / not applicable Multiple Sclerosis Enrolling by invitation
Est. primary completion 2027-07-08 ·
NCT03032601 ·
CT.gov ↗ What to watch Phase 4 Psychosis Not yet recruiting
Est. primary completion 2027-07-31 ·
NCT06546475 ·
CT.gov ↗ What to watch 2028 (2) July 2028 (1) Phase 2/3 Autism Spectrum Disorder Enrolling by invitation
Est. primary completion 2028-07-31 ·
NCT05494398 ·
CT.gov ↗ What to watch December 2028 (1) Phase 2 Schizoaffecitve Disorder, Schizophrenia and Schizoaffective Disorder, Schizophrenia and Predominant Negative Symptoms Recruiting
Est. primary completion 2028-12 ·
NCT07759895 ·
CT.gov ↗ What to watch 2030 (1) July 2030 (1) Phase 3 Dengue, Severe Dengue, Mosquito-Borne Diseases, Vector Borne Diseases, Arbovirus Infections, Flavivirus Infections, RNA Virus Infections … Not yet recruiting
Est. primary completion 2030-07-31 ·
NCT07543458 ·
CT.gov ↗ What to watch See the full readout calendar ↗
All registered studies Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.
Phase 3 (19) Phase 2/3 (7) Phase 2 (24) Phase 1/2 (6) Phase 1 (18) Phase 4 (15) Early phase / not applicable (33) Appears in other studies (6)